MaxCyte MXCT Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by MaxCyte in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about MaxCyte's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MaxCyte's operating lease right-of-use asset amortization?
- MaxCyte (MXCT) reported operating lease right-of-use asset amortization of $221K in Q1 2026.
- How has MaxCyte's operating lease right-of-use asset amortization changed year-over-year?
- MaxCyte's operating lease right-of-use asset amortization increased by 22.1% year-over-year, from $181K to $221K.
- What is the long-term trend for MaxCyte's operating lease right-of-use asset amortization?
- Over 3 years (2022 to 2025), MaxCyte's operating lease right-of-use asset amortization has grown at a 1.5% compound annual growth rate (CAGR), from $767K to $802K.